Antiretroviral News and Research

RSS

PREZISTA/ritonavir once-daily dosing for HIV-1 receives FDA approval for treatment in no DRV RAM adults

Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P., announced today that the U.S. Food and Drug Administration (FDA) has approved a revision to the dosing recommendation to include once-daily dosing of PREZISTA® (darunavir) tablets in combination with ritonavir for the treatment of human immunodeficiency virus (HIV-1) in treatment-experienced adult patients with no darunavir resistance-associated mutations (DRV RAMs).

13 Dec 2010

Argos' AGS-004 shows feasibility in in vitro models to generate DC from viremic patients

Argos Therapeutics announced today that its Arcelis HIV immunotherapy, AGS-004, showed feasibility in in vitro models to generate fully functional dendritic cells (DC) from viremic patients.

13 Dec 2010

Genetic Immunity to present DermaVir and DermaPrep transdermal delivery system at HIV DART 2010 conference

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week's HIV DART 2010 conference, "Frontiers in Drug Development for Antiretroviral Therapies," in Los Cabos, Mexico. The conference brings international researchers together to discuss the latest developments in the fight against HIV/AIDS.

9 Dec 2010

USAID, PEPFAR and HHS welcome WHO's endorsement of rapid diagnostic test for TB

The United States welcomes the policy statement and roadmap issued today by the World Health Organization (WHO) charting the rollout of the Xpert MTB/RIF rapid diagnostic test for tuberculosis (TB) and rifampicin resistance, a proxy for multidrug resistant tuberculosis (MDR-TB).

9 Dec 2010

VIRxSYS presents study results of VRX1116 at HIV DART 2010

VIRxSYS Corporation, a privately held company developing vaccines and RNA therapies, today presented results from a study of VRX1116 at HIV DART 2010 in Los Cabos, Mexico, showing that vaccinated monkeys challenged with highly pathogenic simian immunodeficiency virus achieve sustained viral load reduction, preservation of the immune system and increased survival compared to controls.

9 Dec 2010

European Commission must stop attacking generic medicines, says ITPC

On International Human Rights Day, as the European Commission (EC) and the Government of India meet in Brussels to finalise a European Union (EU)-India free trade agreement, the International Treatment Preparedness Coalition (ITPC) calls on Indian negotiators to put the right to health of its citizens and of the fifteen million HIV-positive people worldwide needing treatment above the pharmaceutical companies' interests and profits.

8 Dec 2010

Matrix's NDA for Abacavir Sulfate receives tentative FDA approval under PEPFAR

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Abacavir Sulfate Tablets, 60 mg. The NDA is based on the reference listed drug Ziagen® by ViiV Healthcare.

7 Dec 2010

New, HIV-like retroviruses linked to CFS, prostate cancer detected in healthy blood donors

In an unprecedented move, chronic fatigue syndrome patients published a half-page ad in The Washington Post today. The ad brings attention to new, HIV-like retroviruses, including XMRV, which have been linked to CFS and aggressive prostate cancer, and have been detected in healthy blood donors.

6 Dec 2010

HIV prevention programs worldwide are missing MSMs, survey finds

An online survey of men who have sex with men and their health service providers shows that the majority of respondents said most "gay men worldwide don't have access to HIV testing, counseling or free condoms and lubricant, a new study finds," according to a report by the Global Forum on MSM & HIV, HealthDay/Businessweek reports.

4 Dec 2010

White House marks World AIDS Day

Commemorating World AIDS Day on Wednesday President Barack Obama called for continuing to fight HIV/AIDS domestically and abroad, Agence France-Presse reports (12/1).

2 Dec 2010

USAID Administrator Shah issues statement on occasion of World AIDS Day

Dr. Rajiv Shah, Administrator of the U.S. Agency for International Development (USAID), released the following statement on the occasion of World AIDS Day.

2 Dec 2010

Advent of HAART leads to decrease in mortality among people living with HIV/AIDS

During the decade since the advent of highly active antiretroviral therapy (HAART), or 1996-2006, mortality among people living with HIV/AIDS (PLWHA) sharply decreased in the United States. So, too, did the percentages of PLWHA deaths attributable to AIDS-defining illnesses, just as there was a marked increase in the percentage of deaths attributable to heart, kidney, and liver disease.

2 Dec 2010

Regular, low-cost preventive medication can protect people with HIV from TB

Children and adults living with HIV can be protected from one of their deadliest threats - tuberculosis (TB) - with a regular, low-cost preventive medication according to new guidelines launched today by the WHO. Of the nearly two million AIDS-related deaths each year, a quarter of them are associated with TB.

2 Dec 2010

U.N. says PMTCT of HIV is achievable; efforts must target millions currently 'falling through the cracks'

A generation of babies could be born free of AIDS if the international community stepped up efforts to provide universal access to HIV prevention, treatment and social protection, the United Nations said on Tuesday, Reuters reports.

2 Dec 2010

Health, HIV and human rights

On World AIDS Day 2010, the global community is focusing attention on protecting human rights of all people affected by HIV.

1 Dec 2010

SPARTAC study examines ways to limit immune system damage in HIV infection

For most people in high-income countries HIV is considered a chronic illness which can be managed with medication. But the virus still causes extensive damage to the immune system, and treatment with antiretrovirals is a lifelong commitment. Once started, usually within three to five years following infection, the course of treatment needs to be strictly followed and taken for life.

1 Dec 2010

PhRMA reports 100 new medicines and vaccines in development for HIV/AIDS

America's biopharmaceutical research companies are working on 100 new medicines and vaccines [video] to treat and prevent HIV/AIDS and related conditions, according to a new report from the Pharmaceutical Research and Manufacturers of America (PhRMA).

1 Dec 2010

Antiretroviral News and Research

PREZISTA/ritonavir once-daily dosing for HIV-1 receives FDA approval for treatment in no DRV RAM adults

Argos' AGS-004 shows feasibility in in vitro models to generate DC from viremic patients

Genetic Immunity to present DermaVir and DermaPrep transdermal delivery system at HIV DART 2010 conference

USAID, PEPFAR and HHS welcome WHO's endorsement of rapid diagnostic test for TB

VIRxSYS presents study results of VRX1116 at HIV DART 2010

European Commission must stop attacking generic medicines, says ITPC

Matrix's NDA for Abacavir Sulfate receives tentative FDA approval under PEPFAR

New, HIV-like retroviruses linked to CFS, prostate cancer detected in healthy blood donors

HIV prevention programs worldwide are missing MSMs, survey finds

White House marks World AIDS Day

USAID Administrator Shah issues statement on occasion of World AIDS Day

Advent of HAART leads to decrease in mortality among people living with HIV/AIDS

Regular, low-cost preventive medication can protect people with HIV from TB

U.N. says PMTCT of HIV is achievable; efforts must target millions currently 'falling through the cracks'

Health, HIV and human rights

SPARTAC study examines ways to limit immune system damage in HIV infection

PhRMA reports 100 new medicines and vaccines in development for HIV/AIDS

Number of people living with HIV/AIDS in Africa to outpace treatment resources by 2020, IOM report finds

Argos commences dosing in Arcelis personalized immunotherapy Phase 2b clinical trial for HIV

Opinions: Obama's Global Fund pledge; harm reduction in Iran; HIV prevention; African development

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News